

해외 바이오의약품 임상 현황 (2020.08.03~2020.08.09)

한국바이오의약품협회, 2020.8.11.
출처: ClinicalTrials.gov

○ 미국 16건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04479358	Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19	COVID-19	Drug: Tocilizumab Other: Standard of Care	University of Chicago	Phase 2
NCT04471974	ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer	Castration-Resistant Prostate Carcinoma Metastatic Prostate Adenocarcinoma Metastatic Prostate Small Cell Carcinoma Stage IV Prostate Cancer AJCC v8 Stage IVA Prostate Cancer AJCC v8 Stage IVB Prostate Cancer AJCC v8	Drug: BET Bromodomain Inhibitor ZEN-3694 Drug: Enzalutamide Biological: Pembrolizumab	Rahul Aggarwal Zenith Epigenetics Merck Sharp & Dohme Corp. U.S. Army Medical Research and Development Command University of California, San Francisco	Phase 2
NCT04460105	Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia	COVID-19 Pneumonia	Drug: Lanadelumab Other: Placebo	Shire Takeda Development Center Americas (TDCA) Takeda	Phase 1
NCT04397796	Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation	COVID	Biological: BM-Allo.MSC Biological: Placebo	NantKwest, Inc.	Phase 1
NCT04077021	First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer	Castration-Resistant Prostatic Cancer	Drug: CCW702	Calibr, a division of Scripps Research	Phase 1
NCT04501978	Therapeutics for Inpatients With COVID-19	Covid19	Drug: LY3819253 Drug: Placebo Drug: Remdesivir	National Institute of Allergy and Infectious Diseases (NIAID) International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) University of Copenhagen Medical Research Council Kirby Institute Washington D.C. Veterans Affairs Medical Center AIDS Clinical Trials Group National Heart, Lung, and Blood Institute (NHLBI) US Department of Veterans Affairs Prevention and Early Treatment of Acute Lung Injury (PETAL) Cardiothoracic Surgical Trials Network (CTSN)	Phase 3
NCT04488575	Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection	Covid19	Drug: EDP1815 Drug: Placebo	Evelo Biosciences, Inc.	Phase 2
NCT04468958	Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants	COVID-19 SARS-CoV2	Biological: SAB-185 Other: Normal saline	SAb Biotherapeutics, Inc. Department of Health and Human Services Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB)	Phase 1
NCT04250636	3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals	Human Immunodeficiency Virus	Drug: 3BNC117-LS Drug: 10-1074-LS	Rockefeller University National Institute of Allergy and Infectious Diseases (NIAID) Weill Medical College of Cornell University Perelman School of Medicine University of Pennsylvania	Phase 1
NCT04157127	Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma	Pancreatic Adenocarcinoma Pancreatic Cancer	Biological: Autologous DC vaccine	Baylor College of Medicine Cancer Cures for Kids	Phase 1
NCT04505813	Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma	Relapsed Refractory Multiple Myeloma	Biological: NEXI-002 T Cells	Neximmune Inc.	Phase 1 Phase 2
NCT04350138	Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection	Gonococcal Infection	Biological: Meningococcal Group B Vaccine Other: Placebo	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
NCT04503551	A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm	Diabetic Retinopathy	Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab Drug: Intravitreal Ranibizumab 0.5 mg Injection	Hoffmann-La Roche	Phase 3
NCT04492475	Adaptive COVID-19 Treatment Trial 3 (ACTT-3)	COVID-19	Drug: Interferon beta-1a Other: Placebo Drug: Remdesivir	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3
NCT04433585	A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)	Systemic Lupus Erythematosus	Drug: LY3471851 Drug: Placebo	Eli Lilly and Company Nektar Therapeutics	Phase 2
NCT04193189	B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVE): Evaluation of HEPLISAV-B	HIV Infection Hepatitis B	Biological: HEPLISAV-B Biological: ENGERIX-B	National Institute of Allergy and Infectious Diseases (NIAID) Dynavax Technologies Corporation	Phase 3

○ 독일 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04501107	A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus	Type 1 Diabetes	Drug: Administration of BioChaperone insulin lispro reconstituted with Humalog® (IMP1) Drug: Administration of Ready-to-use BioChaperone insulin lispro (IMP2) Drug: Administration of US-approved Humalog® (IMP3) Drug: Administration of EU-approved Humalog® (IMP4)	Adocia	Phase 1
NCT04433585	A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)	Systemic Lupus Erythematosus	Drug: LY3471851 Drug: Placebo	Eli Lilly and Company Nektar Therapeutics	Phase 2

해외 바이오의약품 임상 현황 (2020.08.03~2020.08.09)

한국바이오의약품협회, 2020.8.11.
출처: ClinicalTrials.gov

○ 중국 4건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04506138	Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma	Esophageal Squamous Cell Carcinoma	Drug: Camrelizumab Drug: Paclitaxel for Injection (Albumin Bound) Drug: Carboplatin	Zhejiang Cancer Hospital	Phase 1 Phase 2
NCT04435197	Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma	Esophageal Squamous Cell Carcinoma	Drug: Pembrolizumab Injection	Ruijin Hospital Fujian Medical University Union Hospital Zhejiang University The First Affiliated Hospital of Anhui Medical University The First Affiliated Hospital of Nanchang University	Phase 2
NCT04212598	The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer	Esophageal Squamous Cell Carcinoma	Drug: Sintilimab	Wuhan University	Phase 2
NCT04235959	A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus	Diabetes Mellitus, Type 2	Drug: Tirzepatide Drug: Placebo	Eli Lilly and Company	Phase 1

○ 일본 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04484935	Safety and Tolerability Study of RSV Prophylactic Drug for Immunocompromised Children	RSV Infection	Drug: Nirsevimab	MedImmune LLC QVIA Services Japan K.K.	Phase 2
NCT04433585	A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)	Systemic Lupus Erythematosus	Drug: LY3471851 Drug: Placebo	Eli Lilly and Company Nektar Therapeutics	Phase 2